Artivion (NYSE:AORT) SVP Sells $2,133,815.04 in Stock

Artivion, Inc. (NYSE:AORT) SVP Marshall Stanton sold 47,376 shares of the business’s stock in a transaction on Friday, November 21st. The shares were sold at an average price of $45.04, for a total value of $2,133,815.04. Following the completion of the sale, the senior vice president directly owned 44,753 shares in the company, valued at approximately $2,015,675.12. This represents a 51.42% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Artivion Price Performance

Shares of AORT traded up $0.68 during trading hours on Monday, hitting $45.81. The stock had a trading volume of 349,331 shares, compared to its average volume of 432,679. The stock has a market capitalization of $2.17 billion, a price-to-earnings ratio of -109.07 and a beta of 1.65. Artivion, Inc. has a 52 week low of $21.97 and a 52 week high of $48.04. The company has a debt-to-equity ratio of 0.52, a current ratio of 4.78 and a quick ratio of 3.48. The company’s fifty day moving average is $42.97 and its two-hundred day moving average is $37.04.

Artivion (NYSE:AORT) last posted its quarterly earnings data on Thursday, November 6th. The company reported $0.16 earnings per share for the quarter, topping the consensus estimate of $0.14 by $0.02. The company had revenue of $113.39 million during the quarter, compared to analyst estimates of $110.71 million. Artivion had a negative net margin of 4.43% and a positive return on equity of 5.70%. The business’s revenue was up 18.9% on a year-over-year basis. Artivion has set its FY 2025 guidance at EPS. On average, analysts anticipate that Artivion, Inc. will post 0.37 EPS for the current year.

Analysts Set New Price Targets

Several equities research analysts have weighed in on the stock. JMP Securities raised their price objective on shares of Artivion from $42.00 to $47.00 and gave the company a “market outperform” rating in a research report on Friday, October 10th. Citizens Jmp boosted their target price on Artivion from $47.00 to $53.00 and gave the stock a “market outperform” rating in a research report on Friday, November 7th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Artivion in a report on Wednesday, October 8th. Needham & Company LLC lifted their price target on shares of Artivion from $50.00 to $58.00 and gave the company a “buy” rating in a research note on Friday, November 7th. Finally, LADENBURG THALM/SH SH cut Artivion from a “buy” rating to a “neutral” rating and upped their price objective for the stock from $32.00 to $38.80 in a research report on Wednesday, August 13th. Seven equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $49.11.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. Caitong International Asset Management Co. Ltd bought a new position in shares of Artivion during the third quarter worth approximately $27,000. Hancock Whitney Corp bought a new position in shares of Artivion during the third quarter worth approximately $212,000. Dark Forest Capital Management LP bought a new stake in shares of Artivion in the third quarter valued at approximately $1,623,000. Voloridge Investment Management LLC grew its position in Artivion by 442.9% during the third quarter. Voloridge Investment Management LLC now owns 220,076 shares of the company’s stock worth $9,318,000 after buying an additional 179,541 shares in the last quarter. Finally, Wasatch Advisors LP raised its holdings in Artivion by 24.4% in the 3rd quarter. Wasatch Advisors LP now owns 282,391 shares of the company’s stock valued at $11,956,000 after acquiring an additional 55,408 shares in the last quarter. Institutional investors and hedge funds own 86.37% of the company’s stock.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.